Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.7552W HIGH $6.24
Volume
20.41 K
Value Traded
40.52 K
Short % Float
0.01%
-1.61%Week
-25.61%1 Month
-24.87%3 Month
-35.79%6 Month
-100%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.99 M
EPS (TTM)
-2.70
P/E Ratio
-
Ent. Value
-8.49 M
Total Shares
3.98 M
Float Shares
3.13 M
Insiders
21.51%
Institutions
7.64%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
REVB Catalyst Timeline
Dated clinical, regulatory and corporate events for Revelation Biosciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Revelation Biosciences, Inc.
197Total events
4Upcoming
37Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲FDA Feedback ReceivedGeminiFDA Meeting
Agreement with FDA on single adaptive Phase 2/3 study design for Gemini in AKI
acute kidney injurysource ↗
●Trial InitiationGeminiTrial
Initiated discussions with potential CROs for single adaptive Phase 2/3 study
acute kidney injurysource ↗
◆Oral PresentationGeminiPresentation
Presentation of new clinical data on Gemini for AKI and CKD at AKI & CRRT 2026
acute kidney injury (AKI) and chronic kidney disease (CKD)source ↗
▲Poster PresentationGeminiPresentation
Presented additional positive data analysis from PRIME Study at AKI & CRRT 2026
acute kidney injurysource ↗
●Oral PresentationGeminiPresentation
Fireside chat at 38th Annual ROTH Conference
acute kidney injurysource ↗
●Quarterly UpdateCorporate
Financial results for three and twelve months ended December 31, 2025
▲SPA AgreementGeminiFDA Meeting
FDA agreement on approval pathway for Gemini in AKI
Acute Kidney Injury (AKI)source ↗
▲Full ResultsGeminiClinical Data
Positive results from PRIME clinical study in late-stage CKD patients
chronic kidney diseasesource ↗
▲SPA AgreementGeminiFDA Meeting
Agreement with FDA on single adaptive Phase 2/3 study for approval of Gemini for AKI
acute kidney injurysource ↗
▲FDA Feedback ReceivedGeminiFDA Meeting
Productive and successful meeting with FDA in December 2025
Acute Kidney Injurysource ↗
▲Topline ReadoutGeminiClinical Data
Announced Groundbreaking Top-line Results from PRIME Clinical Study
chronic kidney diseasesource ↗
●Quarterly UpdateCorporate
Financial results for three and nine months ended September 30, 2025
▲AdCom CancelledAdvisory Committee
Cancellation of adjourned special meeting of stockholders due to technical difficulty
◆Quarterly UpdateCorporate
Special Meeting of Stockholders adjourned from October 15, 2025 to October 29, 2025
◆Oral PresentationGeminiPresentation
Corporate update webcast/conference call to review PRIME top-line data
chronic kidney disease (stage 3 and 4)source ↗
▲Topline ReadoutGeminiClinical Data
Positive topline results from PRIME Phase 1b study of Gemini in stage 3 and 4 CKD patients
chronic kidney disease (stage 3 and 4)source ↗
▼Equity OfferingCorporate
Received gross proceeds of $9.6 million from warrant inducement in September 2025
▲Enrollment CompleteGeminiTrial
Completed dosing of patients in PRIME Phase 1b Clinical Study of Gemini in CKD Patients
chronic kidney diseasesource ↗
◆Enrollment CompleteGeminiTrial
PRIME Phase 1b study of Gemini in CKD patients expected to complete enrollment this month
chronic kidney disease (CKD)source ↗
◆Topline ReadoutGeminiClinical Data
Topline data from PRIME Phase 1b study expected shortly after enrollment completion
chronic kidney disease (CKD)source ↗
◆Enrollment CompleteGeminiTrial
Anticipated completion of enrollment in PRIME Phase 1b study
chronic kidney diseasesource ↗
◆Topline ReadoutGeminiClinical Data
Topline data from PRIME Phase 1b study expected mid-year
chronic kidney diseasesource ↗
▲First Patient DosedGeminiTrial
Completed dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients
chronic kidney diseasesource ↗
▼Equity OfferingCorporate
Received gross proceeds of $4 million from public offering in May 2025
◆Topline ReadoutGeminiClinical Data
Top-line data from PRIME Phase 1b study in CKD patients expected by mid 2025
Chronic Kidney Disease (CKD)source ↗
▲First Patient DosedGeminiTrial
First patient dosed in PRIME Phase 1b study of Gemini
Chronic Kidney Disease (Stage 3 and 4)source ↗
▲First Patient DosedGeminiTrial
First patient dosing expected mid-February
Chronic Kidney Disease (CKD)source ↗
▲Trial InitiationGeminiTrial
Commencement of PRIME Phase 1b clinical study of Gemini in CKD patients
Chronic Kidney Disease (Stage 3 and 4)source ↗
▲Trial CompletionGeminiTrial
Completed Phase 1b clinical study in CKD patients
chronic kidney diseasesource ↗
◆FDA Feedback ReceivedGeminiFDA Meeting
Meeting with FDA later this year to gain agreement on clinical development path to registration
acute kidney injurysource ↗
◆End Of Phase 1 MeetingGeminiFDA Meeting
End of Phase 1 meeting with FDA scheduled for later this year
chronic kidney disease (stage 3 and 4)source ↗
◆Topline ReadoutGeminiClinical Data
Phase 1b PRIME clinical study topline data expected this summer
chronic kidney diseasesource ↗
▲First Patient DosedGeminiTrial
PRIME Phase 1b study initiated in CKD patients
Chronic Kidney Diseasesource ↗
◆Trial InitiationGeminiTrial
Initiation of Phase 1b clinical study in chronic kidney patients
chronic kidney diseasesource ↗
▲First Patient DosedGeminiTrial
First patient dosed in PRIME Phase 1b study of Gemini in CKD patients
chronic kidney diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How REVB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-06-30 | Gemini | Phase 1b data readout | Phase 1b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
F16 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 98%
Micro Cap(rank 645 of 658)
Percentile Rank
Revelation Biosciences, Inc. has significant pipeline risk (16/100), with $99M risk-adjusted pipeline value, led by Gemini in Renal Insufficiency, Chronic (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gemini Small moleculeCompletedNCT06863467 | Renal Insufficiency, Chronic | Phase 1 | COMPLETED | 40 | Jul 22, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every REVB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Gemini | acute kidney injury and chronic kidney disease | 2026-01-15 | normalization of the hyperinflammatory state in stage 3 and 4 CKD patients and restoration of immunocompetenceRead More | Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Rolke JamesDirector, Officer (Chief Executive Officer) | Disposition | -10,115 214,738 held | $1.13 | 04/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in REVB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in REVB for Q2 2026. | ||||
REVB Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How REVB ranks across every disease it competes in
Competitive Position is a premium feature
See how REVB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialREVB News
REVBRevelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study
Revelation Biosciences has appointed Avance Clinical as the contract research organization for its Phase 2/3 TITAN study. This study will evaluate the efficacy of Gemini in treating patients with acute kidney injury (AKI). The partnership is expected to strengthen the clinical development process for this important therapy.
Read more →REVBRevelation Biosciences, Inc. Announces Financial Results For the Three and Six Months Ended June 30, 2026
Revelation Biosciences, Inc. reported its financial results for the second quarter of 2026, highlighting the formation of an Acute Kidney Injury Advisory Board and ongoing Phase 2/3 clinical study preparations. The company noted a potential $94 billion market for its product, Gemini, although it also reported increased net losses and cash used for operations compared to the previous year.
Read more →REVB▲ +7.4%on this news· ran to +19% by day 1shared move
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
Revelation Biosciences announced a $94 billion total addressable market for its treatment, Gemini, targeting Stage 2 and Stage 3 Acute Kidney Injury (AKI). The independent assessment highlighted significant unmet medical needs and the absence of FDA-approved treatments for AKI. Medical professionals expressed strong interest in Gemini, which is anticipated to be widely adopted in hospital formularies.
Read more →REVBRevelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Revelation Biosciences, Inc. announced the approval of inducement grants totaling 108,000 restricted stock units to three new non-executive employees. These grants were made under the 2026 Equity Inducement Plan as a material inducement for their employment. The RSUs will vest over two years, aligning with the employees' continued service.
Read more →REVBRevelation Biosciences Announces Adoption of Stockholder Rights Plan
Revelation Biosciences has adopted a stockholder rights plan to protect its shareholders. This plan allows stockholders to realize the full value of their investments and reduces the risk of hostile takeovers. The rights will be exercisable if any person acquires 10% or more of the company's stock without board approval. The plan is designed to ensure fair evaluations of any potential acquisition offers.
Read more →REVBRevelation Biosciences Expands Acute Kidney Injury Advisory Board
Revelation Biosciences has expanded its Acute Kidney Injury Advisory Board by adding Dr. Peter Pickkers and Dr. Lui Forni. This move aims to enhance the company's clinical strategy and improve patient outcomes as they prepare for a Phase 2/3 clinical trial of their treatment, Gemini. The board's expertise will help design effective studies addressing AKI.
Read more →REVBRevelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders
Revelation Biosciences, Inc. has released a corporate update highlighting its progress with Gemini, a drug aimed at treating acute kidney injury (AKI). Following a productive FDA meeting, the company plans to initiate an adaptive design clinical study in late 2026. The update emphasizes the drug's potential to address significant unmet medical needs in kidney health and its promising market prospects.
Read more →REVB▼ -5.9%on this news
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026
Revelation Biosciences, Inc. reported its financial results for Q1 2026, highlighting a significant agreement with the FDA for a Phase 2/3 study of its product Gemini aimed at treating acute kidney injury. The company raised $6.7 million through a warrant inducement and presented positive data at a recent conference. However, it also reported a net loss of $3 million, which is higher than the previous year.
Read more →REVB▼ -7.2%on this news
Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board
Revelation Biosciences has established an Acute Kidney Injury Advisory Board to support its Phase 2/3 clinical trial for Gemini, a treatment aimed at improving patient outcomes. The board comprises esteemed nephrologists and critical care physicians who will oversee the trial's design and implementation. This initiative underscores the company's commitment to addressing the unmet medical needs in acute kidney injury treatment.
Read more →REVB▲ +5.3%on this news
Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study
Revelation Biosciences presented positive data from its PRIME Study at a nephrology conference, demonstrating that its product, Gemini, effectively normalizes inflammation and restores immune function in patients with chronic kidney disease. The study showed significant reductions in elevated cytokines and improved responsiveness to immune stimulation after treatment. The company plans to initiate a pivotal clinical study for acute kidney injury later this year.
Read more →REVB▼ -8.2%on this news
REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
Revelation Biosciences, Inc. will participate in a fireside chat at the 38th Annual Roth Conference on March 24, 2026. The event will take place at 2:00 p.m. PT in Dana Point, CA, and will be webcast live. The company focuses on rebalancing inflammation with its proprietary formulation, Gemini, targeting various health conditions.
Read more →REVBRevelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
Revelation Biosciences, Inc. will participate in the 38th Annual Roth Conference on March 23-24, 2026. CEO James Rolke and CFO Chester S. Zygmont, III will host a fireside chat on March 24 at 2:00 p.m. PT. The event will be webcast live and available on their website for investors.
Read more →REVB▼ -5.7%on this news
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025
Revelation Biosciences, Inc. announced its financial results for the year ending December 31, 2025, reporting a net loss of $8.9 million. The company highlighted a positive outcome from its PRIME clinical study focused on chronic kidney disease and secured FDA agreement for an adaptive Phase 2/3 study for its product Gemini, aimed at treating acute kidney injury. Additionally, the company received $6.7 million through a warrant inducement, increasing its cash reserves to $10.7 million, projected to support operations into early 2027. Despite showing progress in clinical trials, the company continues to face significant financial losses.
Read more →REVBRevelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026
Revelation Biosciences Inc. announced a 1-for-4 reverse stock split effective January 28, 2026. This move is intended to boost the market price per share to meet Nasdaq's minimum bid requirements. The adjustment will apply uniformly to all stockholders, ensuring no change in their relative equity interests. The company continues to focus on its clinical programs.
Read more →REVB▼ -14.8%on this news· ran to -26% by day 3shared move
Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds
Revelation Biosciences Inc. has announced the exercise of warrants, generating $11 million in gross proceeds. The company will issue up to 13,065,000 shares at a reduced price of $0.86 per share. Additionally, holders of the existing warrants will receive new Class J warrants, which can be exercised for more shares in the future. The transaction is expected to close by January 26, 2026.
Read more →REVBRevelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI
Revelation Biosciences has secured an agreement with the FDA for the approval pathway of Gemini, a treatment for Acute Kidney Injury (AKI). The agreement includes a composite endpoint of death and/or dialysis need and allows for a single Phase 2/3 adaptive study design. This development positions Gemini as a potential first-line therapy for AKI, addressing a significant unmet medical need.
Read more →REVBRevelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)
Revelation Biosciences Inc. will present new clinical data on its product Gemini at the International Conference on Advances in Critical Care Nephrology in San Diego. The data highlights Gemini's potential to normalize hyperinflammation in CKD patients and its therapeutic benefits for acute kidney injury. This presentation marks a significant step in the company's strategy for advancing clinical studies.
Read more →REVBRevelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - January 12, 2026
Revelation Biosciences announced an inducement grant of 90,000 restricted stock units to a new non-executive employee, approved by its Compensation Committee. This grant, made outside the company's equity incentive plan, is intended to encourage the employee's acceptance of the job. The RSUs will vest over two years, contingent on continued employment.
Read more →REVBRevelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development
Revelation Biosciences has commenced GMP manufacturing of its drug candidate, Gemini, and placebo to support later stage clinical trials. This initiative is pivotal for advancing their pipeline, particularly for treating acute kidney injury. The company recently consulted with the FDA to align on the regulatory pathway for Gemini's development.
Read more →REVBTranscript of Corporate Update
The corporate update highlights the successful completion of a Phase 1b clinical study for Gemini in CKD patients, demonstrating promising results in managing inflammation. The company is in good financial standing and is preparing for a forthcoming FDA meeting to discuss the clinical and regulatory pathway for Gemini, particularly for treating acute kidney injury. Looking ahead to 2026, the company plans to build the necessary infrastructure for later-stage clinical studies, including manufacturing and investigator recruitment.
Read more →About Revelation Biosciences, Inc.
Headquarters4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO, CA, 92122
BIOPHARMAWATCH ELITE PLUS
Trade the next REVB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime